Medtronic today announced it received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity™ blood pressure procedure. Symplicity Spyral is the first RDN system in China to receive NMPA approval. The company intends to go through the provincial registration process and expects sales of Symplicity Spyral in China to be modest in the short-term. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Permalink

Disclaimer

Medtronic plc published this content on 06 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2024 13:02:02 UTC.